Opendata, web and dolomites

SPRAYNERGY

Translational synergistic growth factor microenvironments for bone regeneration

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SPRAYNERGY project word cloud

Explore the words cloud of the SPRAYNERGY project. It provides you a very rough idea of what is the project "SPRAYNERGY" about.

human    defect    stages    differentiation    translational    engineered    commercialisation    sequester    fibronectin    safe    critical    direct    spray    surgeon    planning    dr    pea    material    enhances    poly    regenerate    region    size    stem    serious    later    versatile    erc    coated    grant    integrin    domain    lower    murine    bulk    layer    encountered    vascularisation    vivo    overcome    patent    localised    recombinant    fn    licensed    clinical    acrylate    union    sme    integrins    morphogenetic    gf    taragenyx    construct    combination    competitive    doses    filed    patients    co    gfs    protein    engineering    appraisal    binding    commercial    polymer    presentation    teamed    functional    morphogenesis    safer    hurdle    cell    regeneration    receptors    bone    induce    fabricate    rhbmp2    route    clinic    complications    simultaneous    scaling    rhbmp    synergy    degradable    model    tissue    standpoint    nanometric    meek    powerful    defects    signalling    shown    ethyl    ltd   

Project "SPRAYNERGY" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY OF GLASGOW 

Organization address
address: UNIVERSITY AVENUE
city: GLASGOW
postcode: G12 8QQ
website: www.gla.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 148˙783 €
 EC max contribution 148˙783 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-PoC
 Funding Scheme ERC-POC
 Starting year 2016
 Duration (year-month-day) from 2016-06-01   to  2017-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY OF GLASGOW UK (GLASGOW) coordinator 148˙783.00

Map

 Project objective

We propose a robust polymer-based system that allows a safer delivery of recombinant human bone morphogenetic protein-2 (rhBMP2) for bone tissue engineering. We have teamed up with a surgeon (Dr. Meek) and an SME (Taragenyx Ltd.) in the planning stages, for the appraisal of the proposal from a translational standpoint. Later, Taragenyx will also be involved with scaling-up and commercialisation. We filed a patent covering the technology, and licensed Taragenyx its exploitation. rhBMP2 is a powerful human growth factor (GF) essential in tissue morphogenesis and used to promote bone growth in clinical applications. Current clinical delivery has encountered serious complications associated with the high doses used. We have developed a system that allows the effective presentation of GFs in combination with the integrin binding domain of fibronectin (FN), promoting simultaneous and co-localised signalling between GF receptors and integrins. We have shown the ability of Poly(ethyl acrylate) PEA to organise FN and sequester rhBMP2 in synergy with the integrin binding region to direct stem cell differentiation. This technology enhances bone regeneration and vascularisation with lower rhBMP-2 doses. With this understanding we have engineered a system to regenerate a bone critical size defect in a murine model. Results were comparable to the higher doses used in the clinic, which makes the system safe, effective and more competitive than current commercial products. PEA is however a non-degradable material, a major hurdle to be overcome for many potential applications. We will fabricate a degradable construct spray-coated with a nanometric layer of this functional material to induce and direct bone growth – as already shown for the bulk polymer in our ERC Grant, and investigate in vivo the engineered systems. Overall, we will develop a safe and versatile bone system for clinical use in patients with non-union bone defects, and set a route towards commercialisation.

 Publications

year authors and title journal last update
List of publications.
2018 Zhe A. Cheng, Andres Alba-Perez, Cristina Gonzalez-Garcia, Hannah Donnelly, Virginia Llopis-Hernandez, David W. Shields, Laura Ruiz-Cantu, Andrew Reid, James F. C. Windmill, Elena S. Addison, Sandra Corr, William G. Marshall, Matthew J. Dalby and Manuel Salmeron-Sanchez
Engineering nanoscale coatings for ultra-low-dose BMP-2-driven regeneration of critical-size bone defects
published pages: , ISSN: 2095-6231, DOI:
Nature: Bone Research (In review) 2019-06-14

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SPRAYNERGY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SPRAYNERGY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More  

RODRESET (2019)

Development of novel optogenetic approaches for improving vision in macular degeneration

Read More